Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED (CSL)
Mes dernières consult.
Most popular
  Report  
End-of-day quote. End-of-day quote  - 05/25
183.4 AUD   +0.16%
05/17CSL : Raises FY18 Profit Goal
DJ
04/27CSL : Behring, Leader in Rare Diseases, Showcases Innovations in Neu..
AQ
04/19CSL : Appointment of Company Secretary
PU
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
05/21/2018 05/22/2018 05/23/2018 05/24/2018 05/25/2018 Date
186.12(c) 184.33(c) 182.3(c) 183.1(c) 183.4 Last
782 241 908 672 817 465 808 040 2 053 651 Volume
+1.73% -0.96% -1.10% +0.44% +0.16% Change
More quotes
Financials (USD)
Sales 2018 7 669 M
EBIT 2018 2 297 M
Net income 2018 1 715 M
Debt 2018 3 321 M
Yield 2018 1,25%
Sales 2019 8 300 M
EBIT 2019 2 590 M
Net income 2019 1 966 M
Debt 2019 3 025 M
Yield 2019 1,41%
P/E ratio 2018 36,63
P/E ratio 2019 32,09
EV / Sales2018 8,60x
EV / Sales2019 7,91x
Capitalization 62 614 M
More Financials
Company
CSL Ltd. is a biopharmaceutical company.It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions.The company operates its business through two segments: CSL Behring and bioCSL.The CSL Behring segment provides... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of CSL Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on CSL LIMITED
05/17CSL : Raises FY18 Profit Goal
DJ
05/10CSL : Patent Issued for Method for Improving the Stability of Purified Factor VI..
AQ
05/09CSL : CEVEC and CSL Limited sign exclusive license agreement for production of r..
AQ
05/02CSL : MILITARY $33,436 Federal Contract Awarded to CSL Behring
AQ
04/27CSL : Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular M..
AQ
04/19CSL : Appointment of Company Secretary
PU
04/17CSL : Behring - Life-Saving Medicines Donated for Patients in the Developing Wor..
AQ
04/05CSL : Patent Issued for Reconstituted HDL Formulation (USPTO 9925236)
AQ
03/28CSL : Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CS..
AQ
03/23CSL : Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CS..
AQ
More news
Sector news : Biopharmaceuticals
09:29aAstraZeneca cancer drug hits second goal by extending survival
RE
08:48aPFIZER : Plans to Pay $24 Million To Settle Probe Over Medicare -- WSJ
DJ
06:30aPFIZER : Australian anti-trust watchdog loses appeal against Pfizer over Lipitor..
RE
03:17aPfizer to pay $23.85 million to settle U.S. co-payment kickback probe
RE
05/24PFIZER : to Pay $24 Million to Settle Probe Into Copay Assistance Charities--Upd..
DJ
More sector news : Biopharmaceuticals
Latest Tweets
05/23$1.71 Earnings Per Share Expected for Carlisle Companies $CSL This Quarter  
05/21$CSL +2% & is helping offset the market's losses most. Follows the vaccin..
1
05/21LISTEN: + talk Telstra, CSL and reverse mortgages in lateset episode of the.. 
05/19West Pharmaceutical Services $WST vs. Carlisle Companies $CSL Financial Contr.. 
05/18CSL and Bluescope Steel's 2018 profit upgrades should help bust the misconcep.. 
More tweets
Qtime:145
News from SeekingAlpha
02/14CSL Ltd. ADR 2018 Q2 - Results - Earnings Call Slides 
2017CSL (CSLLY) Investor Presentation - Slideshow 
2017CSL Limited Leader In High Growth Plasma Sales To China 
2017CSL reports Q2 results 
2017CSL (CMXHF) Acquires Wuhan Zhong Yuan Rui De Biological Products - Slideshow 
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | 4-Traders
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 137 $
Spread / Average Target -1,3%
EPS Revisions
Managers
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
John Shine Chairman
David Mark Lamont Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer
David Westbrook Anstice Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED0.00%62 614
BIOGEN-12.84%59 874
ALEXION PHARMACEUTICALS-1.22%26 284
GRIFOLS3.05%18 605
BIOMARIN PHARMACEUTICAL0.21%15 632
WUXI BIOLOGICS CAYMAN INC--.--%12 161

Change consent
getVendorList
getVendorConsents
getConsentData
getPublisherConsents